Ars Pharmaceuticals Stock Earnings Reports

ARS Pharmaceuticals reported Q1 2026 results and commercial progress for neffy. Key points: Q1 total revenue was $22.7M, including $17.5M U.S. net product revenue (3x year-over-year prescription volume). Management is focused on three priorities: expanding access, improving affordability, and increasing prescriber adoption. Access wins include ~90% commercial coverage with 57% without prior authorization, 9 states with Medicaid coverage (Florida added effective July 1), recent EU and Canadian regulatory approvals for broader use, and a potentially material formulary decision pending with CVS Caremark (Caremark/Zinc) with a targeted July 1 effective date that would remove prior authorizations for many lives. ARS launched a retail program to guarantee a $199 maximum cash price at retail pharmacies for patients with rejected commercial claims to reduce abandonment and prescribing friction. The sales force was expanded to 148 reps to prioritize high-volume prescribers; ~120,000 U.S. patients currently use neffy (29,500 added in Q1) and >28,000 HCPs have prescribed it. Company highlighted seasonal dynamics (back-to-school as peak), expected refill contributions ramping in H2 2026 into 2027, and global partner milestones (ALK milestone payment tied to EU approval). Q1 R&D was $4.3M; SG&A was $72.2M reflecting commercialization spend. Gross-to-net remains low-to-mid 50% range with ~50% steady-state target. Cash, cash equivalents and short-term investments were $201M; management reiterated a path to cash-flow breakeven by mid-2027, assuming continued access improvements and optimized spend.